5-Propyl-2-amino-4,6-dimethylpyrimidin | 17602-58-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 5-Propyl-2-amino-4,6-dimethylpyrimidin
• 英文别名: 2-amino-4,6-dimethyl-5-propylpyrimidine；4,6-dimethyl-5-propyl-pyrimidin-2-ylamine；4,6-Dimethyl-5-propyl-2-pyrimidinamine；4,6-dimethyl-5-propylpyrimidin-2-amine
• CAS: 17602-58-3
• 化学式: C₉H₁₅N₃
• 分子量: 165.238
• InChiKey: RRFRPXRECQBZSB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  51.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-Propyl-2-amino-4,6-dimethylpyrimidin 、 2-氯-6-氟-苯甲醛 、 巯基乙酸 在 N,N'-二环己基碳二亚胺 作用下， 以 甲苯 为溶剂， 反应 0.25h， 以71.1%的产率得到2-(2-chloro-6-fluorophenyl)-3-(5-propyl-4,6-dimethylpyrimidin-2-yl)thiazolidin-4-one
  参考文献：
  名称：

  Design, microwave-assisted synthesis and HIV-RT inhibitory activity of 2-(2,6-dihalophenyl)-3-(4,6-dimethyl-5-(un)substituted-pyrimidin-2-yl)thiazolidin-4-ones

  摘要：

  A series of novel thiazolidin-4-ones bearing a hydrophobic substituent at 5-position on the 4,6-dimethyl-pyrimidine ring at N-3 (5c-i and 6c-i) were designed on the prediction of QSAR studies, synthesized in good yields of 60.1-85.3% by microwave-assisted one-pot protocol with the combination of using dicyclohexylcarbonimide (DCC) as the promotor, and evaluated as HIV-1 reverse transcriptases inhibitors. The results of in vitro HIV-1 RT kit assay showed that some of the new compounds, such as 5c, 6c, 5d, 6d, 5g, 5h and 6i, could effectively inhibit RT activity. Among them, compounds 5c and 6c where ethyl group existed at 5-position on N-3 pyrimidine ring were the best ones with the IC50 value of 0.26 mu M and 0.23 mu M, respectively. Structure-activity relationship analysis of these analogues suggested that the overall hydrophobicity and steric factor were important to the anti-HIV RT activity. The mechanism of the intramolecular cycloamidation promoted by DCC was also investigated with the key uncyclized intermediate 13. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2009.04.024
• 作为产物：
  描述：

  胍 、 3-正丙基-2,4-戊二酮 以 乙醇 为溶剂， 反应 8.0h， 以26.3%的产率得到5-Propyl-2-amino-4,6-dimethylpyrimidin
  参考文献：
  名称：

  Design, microwave-assisted synthesis and HIV-RT inhibitory activity of 2-(2,6-dihalophenyl)-3-(4,6-dimethyl-5-(un)substituted-pyrimidin-2-yl)thiazolidin-4-ones

  摘要：

  A series of novel thiazolidin-4-ones bearing a hydrophobic substituent at 5-position on the 4,6-dimethyl-pyrimidine ring at N-3 (5c-i and 6c-i) were designed on the prediction of QSAR studies, synthesized in good yields of 60.1-85.3% by microwave-assisted one-pot protocol with the combination of using dicyclohexylcarbonimide (DCC) as the promotor, and evaluated as HIV-1 reverse transcriptases inhibitors. The results of in vitro HIV-1 RT kit assay showed that some of the new compounds, such as 5c, 6c, 5d, 6d, 5g, 5h and 6i, could effectively inhibit RT activity. Among them, compounds 5c and 6c where ethyl group existed at 5-position on N-3 pyrimidine ring were the best ones with the IC50 value of 0.26 mu M and 0.23 mu M, respectively. Structure-activity relationship analysis of these analogues suggested that the overall hydrophobicity and steric factor were important to the anti-HIV RT activity. The mechanism of the intramolecular cycloamidation promoted by DCC was also investigated with the key uncyclized intermediate 13. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2009.04.024

文献信息

• [EN] BENZOXAZEPINES AS INHIBITORS OF MTOR AND METHODS OF THEIR USE AND MANUFACTURE<br/>[FR] BENZOXAZÉPINES EN TANT QU'INHIBITEURS DE MTOR ET PROCÉDÉS DE LEURS UTILISATION ET FABRICATION
  申请人：EXELIXIS INC

  公开号：WO2012071511A1

  公开（公告）日：2012-05-31

  The invention is directed to inhibitors of mTOR and pharmaceutically acceptable salts or solvates thereof, as well as methods of using them. The inhibitors are generally of structural Formula (I) wherein the variables are as defined herein.

  该发明涉及mTOR的抑制剂及其药用盐或溶剂化合物，以及使用它们的方法。这些抑制剂通常具有结构式（I），其中变量如本文所定义。
• BENZOXAZEPINES ASN INHIBITORS OF P13K/M TOR AND METHODS OF THEIR USE AND MANUFACTURE
  申请人：Rice Kenneth D.

  公开号：US20140073628A1

  公开（公告）日：2014-03-13

  The invention is directed to inhibitors of mTOR and pharmaceutically acceptable salts or solvates thereof, as well as methods of using them. The inhibitors are generally of structural formula I and pharmaceutically acceptable salts thereof, wherein the variables are as defined herein.

  本发明涉及mTOR的抑制剂及其药学上可接受的盐或溶剂，以及使用它们的方法。抑制剂通常具有结构式I及其药学上可接受的盐，其中变量如本文所定义。
• Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture
  申请人：EXELIXIS, INC.

  公开号：US20140107100A1

  公开（公告）日：2014-04-17

  The invention is directed 10 Compound's of Formula I: and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds.

  本发明涉及公式I的化合物，以及其药学上可接受的盐或溶剂化物，以及制备和使用这些化合物的方法。
• BENZOXAZEPINES AS INHIBITORS OF mTOR AND METHODS OF THEIR USE AND MANUFACTURE
  申请人：Rice Kenneth

  公开号：US20140018347A1

  公开（公告）日：2014-01-16

  The invention is directed to inhibitors of mTOR and pharmaceutically acceptable salts or solvates thereof, as well as methods of using them. The inhibitors are generally of structural Formula (I) wherein the variables are as defined herein.

  本发明涉及mTOR的抑制剂及其药学上可接受的盐或溶剂，以及使用它们的方法。抑制剂通常具有结构式（I），其中变量如本文所定义。
• [EN] BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE<br/>[FR] BENZOXAZÉPINES EN TANT QU'INHIBITEURS DE PI3K/MTOR, ET LEURS PROCÉDÉS D'UTILISATION ET DE FABRICATION
  申请人：EXELIXIS INC

  公开号：WO2012074869A1

  公开（公告）日：2012-06-07

  The invention is directed to inhibitors of PI3K and mTOR and pharmaceutically acceptable salts or solvates thereof, as well as methods of using them, wherein the inhibitors are of structural Formula I and pharmaceutically acceptable salts thereof, wherein the variables are as defined herein.